Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999-2004

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 26, Issue 3, 2006, Pages 167-174

  Wu, H X ^a   Wu, J ^a   Wong, T ^a   Andonov, A ^b   Li, Q ^a   Dinner, K ^a   Donaldson, T ^a   Paton, S ^a   Ip Chan, J ^c,d   Baptiste, B ^c,e   Furseth, J ^c,f   Poliquin, D ^c,g   Bolesnikov, G ^c   Moffat, B ^c,h  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b Public Health Agency of Canada   (Canada)

^c Capital Health ^*  (Canada)

^d VANCOUVER COASTAL HEALTH   (Canada)

^e Capital Health Edmonton   (Canada)

^f CALGARY HEALTH REGION   (Canada)

^g CITY OF OTTAWA   (Canada)

^h BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABORIGINE; ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CLINICAL FEATURE; COMMUNITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HEPATITIS C VIRUS; HUMAN; INCIDENCE; INFORMATION; MALE; PRIORITY JOURNAL; PUBLIC HEALTH; QUESTIONNAIRE; REGRESSION ANALYSIS; RISK FACTOR; SEXUAL BEHAVIOR; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; VIRUS INFECTION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 34248180132     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0267-7     Document Type: Article

References (22)

1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-567
2. World Health Organization (1999) Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 74:425-427
3. Wong T, Lee SS (2006) Hepatitis C: a review for primary care physicians. CMAJ 174:649-659
4. Zou S, Zhang J, Tepper M et al (2001) Enhanced surveillance of acute hepatitis B and C in four regions in Canada, 1998 to 1999. Can J Infect Dis 12:357-363
5. Gully PR, Tepper ML (1997) Hepatitis C. CMAJ 156:1427-1430
6. Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, Strathdee SA, Currie SL, Schechter MT, O'Shaughnessy MV (2001) Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 165:889-895
7. Goldberg D, Anderson E (2004) Hepatitis C: who is at risk and how do we identify them? J Viral Hepatitis 11(Suppl 1):12-18
8. Alter MJ (1999) Hepatitis C virus infection in the United States. J Hepatol 31(Suppl 1):88-91
9. Waldram JB, Herring DA, Young TK (1995) Aboriginal health in Canada: historical, cultural, and epidemiological perspectives. University of Toronto, Toronto, pp 1-9
10. Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, Heath K, Tyndall MW, O'Shaughnessy MV, Schechter MT (2003) Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 168:19-24
11. Public Health Agency of Canada (2004) HIV/AIDS among Aboriginal persons in Canada: a continuing concern. http://www.phac-aspc.gc.ca/publicat/epiu-aepi/ epi_update_may_04/9_e.html. Cited May 2005
12. Wu HX, Andonov A, Giulivi A, Goedhuis NJ, Baptiste B, Furseth J, Poliquin D, Chan JI, Bolesnikov G, Moffat B, Paton S, Wu J (2005) Enhanced surveillance for childhood hepatitis B virus infection in Canada, 1999-2003. Int J Med Sci 2:143-146
13. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL (1999) Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29:908-914
14. Minuk GY, Uhanova J (2003) Viral hepatitis in the Canadian Inuit and First Nations populations. Can J Gastroenterol 17:707-712
15. Bowker SL, Soskolne CL, Houston SC, Newman SC, Jhangri GS (2004) Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in a northern Alberta population. Can J Public Health 95:188-192
16. Howard G, Anderson RT, Russell G, Howard VJ, Burke GL (2000) Race, socioeconomic status, and cause-specific mortality. Ann Epidemiol 10:214-223
17. Nyamathi AM, Christiani A, Windokun F, Jones T, Strehlow A, Shoptaw S (2005) Hepatitis C virus infection, substance use and mental illness among homeless youth: a review. AIDS 19 (Suppl 3):34-40
18. Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Noel L, Tyndall M, Wild C, Mun P, Baliunas D (2005) Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 82:250-266
19. Adelson N (2005) The embodiment of inequity: health disparities in Aboriginal Canada. Can J Public Health 96(Suppl 2):45-61
20. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER (2001) Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91:42-46
21. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP; German HEP-NET Acute HCV Study Group (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 43:250-256
22. Kamal SM, Fouly AE, Kamel RR Hockenjos B, Al Tawil A, Khalifa KE, He Q, Koziel MJ, El Naggar KM, Rasenack J, Afdhal NH (2006) Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130:632-638